The complete European guidelines on phenylketonuria: diagnosis and treatment
- PMID: 29025426
- PMCID: PMC5639803
- DOI: 10.1186/s13023-017-0685-2
The complete European guidelines on phenylketonuria: diagnosis and treatment
Abstract
Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine. If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems. PKU management differs widely across Europe and therefore these guidelines have been developed aiming to optimize and standardize PKU care. Professionals from 10 different European countries developed the guidelines according to the AGREE (Appraisal of Guidelines for Research and Evaluation) method. Literature search, critical appraisal and evidence grading were conducted according to the SIGN (Scottish Intercollegiate Guidelines Network) method. The Delphi-method was used when there was no or little evidence available. External consultants reviewed the guidelines. Using these methods 70 statements were formulated based on the highest quality evidence available. The level of evidence of most recommendations is C or D. Although study designs and patient numbers are sub-optimal, many statements are convincing, important and relevant. In addition, knowledge gaps are identified which require further research in order to direct better care for the future.
Keywords: European; Guidelines; Hyperphenylalaninemia; Management; PAH deficiency; PKU; Phenylalanine; Phenylalanine hydroxylase deficiency; Phenylketonuria; Recommendations; Sapropterin; Tetrahydrobiopterin; Treatment.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
K. Ahring was/is a member of the European Nutrition Expert Panel (Merck Serono international, Biomarin).
A. Bélanger-Quintana has received honoraria as a speaker from Nutricia, Vitaflo International, Merck Serono and Recordati, and is a member of the European Nutrition Expert Panel (Merck Serono international, Biomarin), the Sapropterin Advisory Board (Merck Serono international, Biomarin), and KAMPER Advisory Board (Merck Serono international, Biomarin).
N. Blau was/is a member of Merck-Serono and Biomarin Scientific Advisory Board for PKU and has received grants and honorarium from Merck-Serono and BioMarin.
A. Bosch was/is a member of Scientific Advisory Boards for Phenylketonuria that are supported by Merck-Serono SA, Biomarin and by Nutricia, and has received grants and honorarium from Merck-Serono and Nutricia.
A. Burlina was/is a member of Scientific Advisory Boards for Phenylketonuria that are supported by Merck-Serono SA, Biomarin and by Nutricia.
J.Campistol has received honoraria as a consultant and/or speaker from Merck-Serono SA and Nutricia/Danone.
M. Giżewska was/is a member of the Scientific Advisory Board for Phenylketonuria that was supported by Merck-Serono SA, and Biomarin and received honoraria as a consultant and/or speaker for Merck Serono SA and Nutricia.
F. Feillet was/is a member of Scientific Advisory Boards for Phenylketonuria (Merck-Serono SA, Biomarin) and has received honoraria from Merck-Serono, Nutricia/Danone and Excemed.
S.C. J. Huijbregts has participated in strategic advisory boards and received honoraria as a consultant and/or speaker for Merck Serono SA, Biomarin and Nutricia.
S. Kearney received honoraria from Merck Serono and Biomarin.
A. MacDonald has received research funding and honoraria from Nutricia, Vitaflo International, Merck Serono, chaired/chairs the European Nutrition Expert Panel (Merck Serono international and later Biomarin), was/is a member of the Sapropterin Advisory Board (Merck Serono international, Biomarin), and is a member of the Advisory Board Element (Danone-Nutricia).
F. Maillot has received honoraria as a consultant and/or speaker from Merck Serono SA, Nutricia and Arla Foods.
A.C. Muntau was/is a member of Scientific Advisory Boards for Phenylketonuria (Merck Serono SA, Arla Foods, Biomarin); has received research funding from Nutricia, Vitaflo International, Merck Serono and has received honoraria from Merck Serono and Arla Foods.
M. van Rijn was a member of the European Nutritionist Expert Panel in PKU (until 2015), is a member of the ELEMENT (Leading Education in Metabolic Error Nutritional Therapy) Steering Committee for Nutricia International, and has received grants and fees for educational and research activities from Nutricia International and Orphan Europe.
F.J. van Spronsen was/is a member of Scientific Advisory Boards for Phenylketonuria (Merck-Serono SA, Arla Foods, Biomarin) and chairs the Scientific Advisory Board for metabolic diseases of Nutricia, has received grants from Nutricia and Merck-Serono SA), and honoraria from Merck-Serono SA, Vitaflo International, Nutricia/Danone, and Excemed.
F. Trefz received grants from Vitaflo and honoraria as a speaker from Merck-Serono SA.
A. van Wegberg received a grant from the ESPKU.
The other authors declare no competing of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5639803/bin/13023_2017_685_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5639803/bin/13023_2017_685_Fig2_HTML.gif)
Similar articles
-
Key European guidelines for the diagnosis and management of patients with phenylketonuria.Lancet Diabetes Endocrinol. 2017 Sep;5(9):743-756. doi: 10.1016/S2213-8587(16)30320-5. Epub 2017 Jan 10. Lancet Diabetes Endocrinol. 2017. PMID: 28082082 Review.
-
Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe.Orphanet J Rare Dis. 2020 Sep 25;15(1):266. doi: 10.1186/s13023-020-01541-2. Orphanet J Rare Dis. 2020. PMID: 32977849 Free PMC article. Review.
-
PKU dietary handbook to accompany PKU guidelines.Orphanet J Rare Dis. 2020 Jun 30;15(1):171. doi: 10.1186/s13023-020-01391-y. Orphanet J Rare Dis. 2020. PMID: 32605583 Free PMC article. Review.
-
Genetic etiology and clinical challenges of phenylketonuria.Hum Genomics. 2022 Jul 19;16(1):22. doi: 10.1186/s40246-022-00398-9. Hum Genomics. 2022. PMID: 35854334 Free PMC article. Review.
-
The management of phenylketonuria in adult patients in Italy: a survey of six specialist metabolic centers.Curr Med Res Opin. 2021 Mar;37(3):411-421. doi: 10.1080/03007995.2020.1847717. Epub 2021 Feb 1. Curr Med Res Opin. 2021. PMID: 33222540
Cited by
-
Comparison of Cost Analysis in Patients with Tetrahydrobiopterin-Responsive and Non-Responsive Phenylketonuria in Turkey.Nutrients. 2024 May 10;16(10):1444. doi: 10.3390/nu16101444. Nutrients. 2024. PMID: 38794682 Free PMC article.
-
Vitamin Status in Patients with Phenylketonuria: A Systematic Review and Meta-Analysis.Int J Mol Sci. 2024 May 7;25(10):5065. doi: 10.3390/ijms25105065. Int J Mol Sci. 2024. PMID: 38791104 Free PMC article. Review.
-
Delays in Newborn Screening for Phenylketonuria from Birth to Diagnosis and Factors Affecting This.Children (Basel). 2024 May 9;11(5):571. doi: 10.3390/children11050571. Children (Basel). 2024. PMID: 38790566 Free PMC article.
-
Poor adherence during adolescence is a risk factor for becoming lost-to-follow-up in patients with phenylketonuria.Mol Genet Metab Rep. 2024 May 9;39:101087. doi: 10.1016/j.ymgmr.2024.101087. eCollection 2024 Jun. Mol Genet Metab Rep. 2024. PMID: 38766496 Free PMC article.
-
Dietary management for pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency, a follow-on from the international consortium guidelines.JIMD Rep. 2024 Apr 3;65(3):188-203. doi: 10.1002/jmd2.12418. eCollection 2024 May. JIMD Rep. 2024. PMID: 38736635 Free PMC article.
References
-
- Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417–1427. - PubMed
-
- de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab. 2010;99(Suppl 1):S86–S89. - PubMed
-
- Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104(Suppl):S2–S9. - PubMed
-
- Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007;30(4):430–438. - PubMed
-
- Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab. 2010;101(2–3):99–109. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical